3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
58
Breast Neoplasms
25
Neoplasms
5
Neoplasm Metastasis
3
Leiomyoma
3
Polycystic Ovary Syndrome
2
Neoplasms by Site
2
Endometrial Neoplasms
2
Cardiovascular Diseases
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Kallmann Syndrome
1
Inflammatory Breast Neoplasms
1
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled